SynthesisClinical nutrition (Edinburgh, Scotland)2011
Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials.
Synthesis in Clinical nutrition (Edinburgh, Scotland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrients · 2025Pooled it
- Mediterranean Diet Pyramid: A Proposal for Italian People. A Systematic Review of Prospective Studies to Derive Serving Sizes.Nutrients · 2019Pooled it
- Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis.Lipids in health and disease · 2017Pooled it
- Pooled it
- Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: systematic review and meta-analysis of prospective studies.Diabetes care · 2012Pooled it
- Pooled it
- Effects of eicosapentaenoic acid on serum levels of selenoprotein P and organ-specific insulin sensitivity in humans with dyslipidemia and type 2 diabetes.Journal of diabetes investigation · 2022Trial
- Marine Oil fromNutrients · 2022Trial
- Trial
- Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial.Lipids in health and disease · 2019Trial
- Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial.The American journal of clinical nutrition · 2017Trial
- Trial
- Associations between school meal-induced dietary changes and metabolic syndrome markers in 8-11-year-old Danish children.European journal of nutrition · 2016Trial
- Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: a double-blind randomised controlled trial.Scientific reports · 2016Trial
- Omega-3 fatty acid supplementation combined with acute aerobic exercise does not alter the improved post-exercise insulin response in normoglycemic, inactive and overweight men.European journal of applied physiology · 2016Trial
- Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans.Diabetes care · 2015Trial
- Trial
- Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes · 2013Trial
- Sex-Specific Dietary Predictors of Blood Glucose Identified Through Decision Tree Modeling in Adults.Nutrients · 2025Article
- Effect of a Diet Supplemented with Marine Omega-3 Fatty Acids on Inflammatory Markers in Subjects with Obesity: A Randomized Active Placebo-Controlled Trial.Healthcare (Basel, Switzerland) · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledBACKGROUND &
aimn-3 PUFA has been shown to decrease the risk of several components of the metabolic syndrome; however, the role of n-3 PUFA on glucose metabolism is not clear. Our aim was to systematically review the effect of n-3 PUFA on IS by conducting a meta-analysis of available RCTs.
methodsWe followed the guidelines of Cochrane's review of systematic interventions. We searched MEDLINE, EMBASE, CENTRAL and clinicaltrials.gov from the beginning of each database until October 2010. Meta-analysis was performed using a random effects model to estimate a pooled SMD and the corresponding 95% CI.
resultsFrom 303 screened citations, 11 RCTs (n = 618) were eligible for inclusion in the analysis. In a pooled estimate, n-3 PUFA intervention had no effects on IS compared to placebo (SMD 0.08, 95% CI -0.11-0.28). Similarly, n-3 PUFA had no effects on IS in sub-group analyses (Type 2 diabetes vs. other population; QUICKI and other test subgroups). In the HOMA subgroup, n-3 PUFA was associated with a statistically significant increase in IS (SMD 0.30, CI 0.03-0.58) when compared to placebo.
conclusionThis meta-analysis is consistent with a lack of n-3 PUFA effects on IS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.